Nimbus Logo

November 13, 2023

Weight Loss

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity - The "SELECT" study broken down

Written by

Jobby John

Hello, I'm Jobby John, the founder of Nimbus Healthcare and a dedicated pharmacist. Today, I am thrilled to share with you the groundbreaking findings of the SELECT Study - a landmark investigation into the effects of semaglutide on cardiovascular outcomes in individuals with overweight or obesity.

Understanding the SELECT Study:

The SELECT Study, officially titled "Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity," is a pivotal clinical trial that has opened new avenues in cardiovascular disease (CVD) management. This study stands out as the first of its kind to evaluate the superiority of an anti-obesity medication - semaglutide - in reducing major adverse cardiovascular events (MACE) in a specific population: individuals with established CVD and overweight or obesity, but without diabetes.

How Semaglutide Works: Understanding the Mechanism of Action

Before delving deeper into the SELECT Study, let's understand how Semaglutide works. Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist. This means it mimics the action of the GLP-1 hormone, which is naturally produced in our body. GLP-1 plays a crucial role in regulating appetite and food intake. When Semaglutide binds to GLP-1 receptors, it enhances the body's natural ability to regulate blood sugar levels and reduce appetite. Consequently, this leads to a reduction in body weight, which is particularly beneficial for individuals with obesity. Additionally, Semaglutide has been shown to improve several cardiovascular risk factors, making it a promising agent in cardiovascular disease management.

Why This Study Matters:

Cardiovascular disease remains a leading cause of morbidity and mortality worldwide, with obesity being a significant risk factor. However, effective and durable interventions targeting obesity-related cardiovascular risk have been elusive. The SELECT Study aims to bridge this gap by exploring the cardiovascular benefits of semaglutide, a GLP-1 receptor agonist known for its weight loss and glycemic control properties.

Key Insights from the SELECT Study:

Target Population: The study enrolled approximately 17,500 volunteers with established CVD and a BMI of ≥27 kg/m². Crucially, these participants did not have diabetes, allowing the study to focus on cardiovascular benefits independent of glycemic control.

Study Design: SELECT is a randomized, double-blind, parallel-group trial comparing semaglutide with placebo, alongside standard cardiovascular care. The primary objective was to demonstrate the superiority of semaglutide in reducing the incidence of MACE.

Innovative Approach: The study's focus on people with obesity but without diabetes is novel. It shifts the paradigm from traditional diabetes-centric cardiovascular risk reduction to a broader population impacted by obesity.

Implications for Healthcare and Future Directions:

The SELECT Study is more than just a clinical trial; it's a beacon of hope for millions struggling with obesity and its cardiovascular complications. As a healthcare professional and founder of Nimbus Healthcare, I see this study as a testament to our commitment to innovative, patient-centric care. We eagerly await the final results, which have the potential to transform our approach to cardiovascular risk management and obesity treatment.


The SELECT Study is a monumental step in our journey to revolutionize cardiovascular and obesity care. It's not just about the scientific findings; it's about how we at Nimbus Healthcare translate these insights into tangible benefits for our patients. This is where our WeightWise RX™ program comes into play, reshaping the healthcare landscape by providing affordable compounded versions of Semaglutide, especially for patients without insurance coverage.

Understanding that access to healthcare is a right, not a privilege, we have taken significant strides to increase accessibility. Our initiative includes providing free medical consultations, ensuring that financial constraints do not hinder anyone from receiving the care they deserve. This program aligns perfectly with the ethos of the SELECT Study, emphasizing the importance of proactive, inclusive, and comprehensive healthcare solutions.

At Nimbus Healthcare, we are more than just providers; we are innovators and caretakers, dedicated to improving health outcomes and quality of life for our community. The SELECT Study's findings and our WeightWise RX™ program are testaments to our commitment to making healthcare accessible, affordable, and effective for all.

Stay Healthy, Stay Informed, Stay Empowered!

Jobby John

Jobby John

PharmD, FACA
Jobby John PharmD, FACA is a clinical pharmacist located in Austin,Texas. He is the CEO and Founder of Nimbus Healthcare. At Nimbus Healthcare, Dr. John brings together a team of highly skilled professionals who share his vision for changing the way healthcare is delivered. By utilizing cutting-edge technologies like artificial intelligence and data analytics, they are able to gather valuable insights that help tailor treatment plans to individual patients. Dr. John is also a fellow of the American College of Apothecaries and he currently serves as the vice president of the Texas Pharmacy Association.

Nimbus in the news

cnncnbcfox businessbloombergamazon prime